… biotech industry in the fields of translational medicine, clinical trial … I to III clinical trials and global development partnerships … Raplixa™ and Genentech's Rituxan®, Tarceva® and Raptiva® programs. … in 2024 for the treatment of multiple solid tumors. …

… of four medical associations and four doctors. In 2000, the FDA succumbed to … who use chemical abortion drugs end up needing medical help afterwards. The adverse … include Pondimin, Zelnorm, Cylert, and Raptiva. Despite reports of many severe …

… US Food and Drug Administration (FDA) has also issued … opportunistic infections. Genentech Inc’s drug, Raptiva approved in 2003 … vaccination during the course of their treatment. After getting a nod for treatment … in the drug’s labeling. Doctors and other …

… medicine. Tim’s work has led to numerous new treatments … to the founding of multiple biotechnology companies (LeukoSite , Scholar … approved therapeutics including Amevive®, Raptiva®, Campath®, Velcade®, and … 057 phase 2 clinical trials, any expectations about …

… biotech industry and with expertise in translational medicine, clinical trial … I to III clinical trials and global development partnerships … Raplixa and Genentech's Rituxan, Tarceva and Raptiva programs. … demonstrated potential as treatments for a wide- …

… a trusted treatment that … doctor immediately,” said Simpson, a professor of pulmonary and critical care medicine … drug market supplied by IQVIA, a pharmaceutical market research firm.  The FDA … ); Siliq (brodalumab); Raptiva (efalizumab); Amevive (alefacept …

… approved by US FDA has a role … denosumab (Prolia, Xgeva), efalizumab (Raptiva), golimumab (Simponi, Simponi Aria … treatment. We also review the current progress in clinical trials, combination of drug … including therapeutic cancer vaccines and mAb therapy …

… biotechnology venture studio focused on translating immunology discoveries into drug … the Department of Medicine at University of … increasing responsibility at Genentech, Inc., including … including Herceptin®, Perjeta®, Raptiva®, Xolair®, Avastin®, Lucentis®, …

… focused on developing novel medicines for oncology and … of APT Pharmaceuticals and Commercial Team Leader at Genentech, managing … successful launches of Xolair®, Raptiva®, Rituxan® RA and Lucentis … is a clinical-stage biotechnology company committed to a …